Core Insights - The company, Changjiang Life Sciences (00775), will present the latest preclinical research data on its cancer vaccine at the AACR 2025 Annual Meeting in Chicago [1][2] - The cancer vaccine targets several proteins, including Preferentially Expressed Antigen in Melanoma (PRAME), programmed cell death-ligand 1 (PD-L1), B7 homolog 3 (B7-H3), and Claudin 6 [1][2] - The company is satisfied with the preclinical efficacy results of the cancer vaccines targeting these proteins and aims to advance them to clinical stages [2] Research and Development - PRAME is a protein highly expressed in melanoma, liver cancer, and blood cancers [1] - PD-L1 is a crucial immune checkpoint protein that inhibits T cell activation in the tumor microenvironment [1] - B7-H3 is another immune checkpoint protein that regulates T cell responses and is often overexpressed in cancers [2] - Claudin 6 is a tight junction protein that regulates epithelial barrier integrity and is overexpressed in breast cancer, lung cancer, and endometrial cancer [2] AI-Driven Vaccine Design - The company will showcase two panels at the AACR 2025 Annual Meeting in collaboration with research partners, highlighting an AI-driven platform for designing cancer vaccines [2] - The use of the AI platform is expected to enhance the immunogenicity and efficacy of the designed vaccines [2] Clinical Trials - The company is accelerating its cancer vaccine research, with multiple therapeutic cancer vaccines at various stages, including clinical and preclinical phases [2] - The cancer vaccine seviprotimut-L is currently in the final research phase, being tested as an adjuvant therapy for melanoma patients post-surgery [2]
长江生命科技(00775)将于美国癌症研究协会2025年度年会上展示研发中癌症疫苗临床前研究最新数据